<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576795</url>
  </required_header>
  <id_info>
    <org_study_id>BMN 270-201</org_study_id>
    <secondary_id>2014-003880-38</secondary_id>
    <nct_id>NCT02576795</nct_id>
  </id_info>
  <brief_title>Gene Therapy Study in Severe Haemophilia A Patients (270-201)</brief_title>
  <official_title>A Phase 1/2, Dose-Escalation, Safety, Tolerability and Efficacy Study of Valoctocogene Roxaparvovec, an Adenovirus-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Patients With Severe Haemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, dose&#xD;
      escalation study in order to determine the safety and efficacy of valoctocogene roxaparvovec&#xD;
      (an Adenovirus-Associated Virus based gene therapy vector in participants with severe&#xD;
      haemophilia A.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03 for 7 years following valoctocogene roxaparvovec infusion.</measure>
    <time_frame>85 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the dose of AAV5-hFVIII-SQ required to achieve expression of FVIII at or above 5% of normal activity (&gt;5 IU/dL) at 16 weeks after infusion.</measure>
    <time_frame>85 Months</time_frame>
    <description>The kinetics, duration and magnitude of AAV-mediated FVIII activity in individuals with haemophilia A will be determined and correlated to an appropriate BMN 270 dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the immune response to the FVIII transgene product and AAV capsid proteins following systemic administration of AAV5-hFVIII-SQ</measure>
    <time_frame>85 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of FVIII replacement therapy during the study</measure>
    <time_frame>85 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding episodes requiring treatment during the study</measure>
    <time_frame>85 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Severe Haemophilia A</condition>
  <arm_group>
    <arm_group_label>valoctocogene roxaparvovec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of valoctocogene roxaparvovec at escalating doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>valoctocogene roxaparvovec</intervention_name>
    <description>Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A</description>
    <arm_group_label>valoctocogene roxaparvovec</arm_group_label>
    <other_name>BMN 270</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males 18 years or older with established severe Haemophilia A (endogenous FVIII level&#xD;
             â‰¤1 IU/dL) as evidenced by their medical history.&#xD;
&#xD;
          2. Treated/exposed to FVIII concentrates or cryoprecipitate for a minimum of 150 exposure&#xD;
             days (EDs)&#xD;
&#xD;
          3. Greater than or equal to 12 bleeding episodes for patients on on-demand FVIII&#xD;
             replacement therapy over the previous 12 months. Does not apply to patients on&#xD;
             prophylaxis&#xD;
&#xD;
          4. No history of inhibitor, and results from a modified Nijmegen Bethesda assay of less&#xD;
             than 0.6 Bethesda Units (BU) 2 consecutive occasions at least one week apart within&#xD;
             the past 12 months&#xD;
&#xD;
          5. Sexually active patients must be willing to use an acceptable method of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Detectable pre-existing immunity to the AAV5 capsid as measured by AAV5 transduction&#xD;
             inhibition or AAV5 total antibodies&#xD;
&#xD;
          2. Any evidence of immunosuppressive disorder or active chronic infection including&#xD;
             hepatis B, hepatitis C, HIV&#xD;
&#xD;
          3. Significant liver dysfunction as defined by abnormal elevation ofliver function tests,&#xD;
             or for patients who have undergone liver imaging or biopsy and found to have evidence&#xD;
             of grade 3 or higher fibrosis&#xD;
&#xD;
          4. Evidence of any bleeding disorder not related to haemophilia A&#xD;
&#xD;
          5. 12. Treatment with any investigational product within 30 days prior to the end of the&#xD;
             screening period, or any previous exposure to any gene transfer therapy&#xD;
&#xD;
          6. Any disease or condition that per the physician's discretion would prevent the patient&#xD;
             from fully complying with the requirements of the study including possible&#xD;
             corticosteroid treatment outlined in the protocol. The physician may exclude patients&#xD;
             unwilling or unable to agree on not using alcohol for the 16-week period following the&#xD;
             viral infusion.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Biological males only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioMarin Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire Hospital</name>
      <address>
        <city>Basingstoke</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2015</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilia A</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Clotting Disorders</keyword>
  <keyword>Blood Disorder</keyword>
  <keyword>Blood Coagulation Disorders, Inherited</keyword>
  <keyword>Blood Coagulation Disorders</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Coagulation Protein Disorders</keyword>
  <keyword>Hemorrhagic Disorders</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <keyword>Factor VIII</keyword>
  <keyword>Coagulants</keyword>
  <keyword>AAV5 vector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

